Development of MHC class II-restricted TCR gene therapy for epstein barr virus associated malignancies

@inproceedings{Williams2016DevelopmentOM,
  title={Development of MHC class II-restricted TCR gene therapy for epstein barr virus associated malignancies},
  author={A. L. Williams},
  year={2016}
}
CD4+ T-cells play a pivotal role within the immune response, and multiple studies have highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful method of specifically redirecting T-cell specificity. We have therefore investigated the anti tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived peptide (PRS), which is expressed in Post… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 350 REFERENCES

Von Andrian, T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases

T. R. Mempel, S. E. Henrickson, U.H
  • 2004
VIEW 18 EXCERPTS
HIGHLY INFLUENTIAL

The immunology of Epstein-Barr virus-induced disease

Taylor, G.S
  • Annu Rev Immunol,
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2

Morgan, R.A
  • Mol Ther,
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL